LYKALABS2023-10-012023-12-31 LYKALABS2023-10-012023-12-31 LYKALABS2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member LYKALABS2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member LYKALABS2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500259 LYKALABS NOTLISTED Lyka Labs Limited Equity 2023-04-01 2024-03-31 2024-02-08 2024-01-31 INR Lakhs Third quarter 12:00:00 13:30:00 2024-02-08 2024-02-08 Not applicable Single segment Pharmaceuticals 2023-10-01 2023-12-31 Unaudited Consolidated 325638000.00 5420000.00 331058000.00 90209000.00 28939000.00 -2354000.00 71668000.00 12783000.00 28416000.00 68532000.00 298193000.00 32865000.00 0.00 32865000.00 10433000.00 2291000.00 12724000.00 0.00 20141000.00 0.00 0.00 0.00 0.00 20141000.00 110000.00 20251000.00 0.00 2331000.00 0.00 0.00 330900000.00 10 0.53 0.53 0.00 0.00 0.53 0.53 1.The above unaudited Consolidated financial results were considered by the Audit Committee at its meeting held today which has been approved and taken on record at the meeting of the Board of Directors held on 8th February, 2024. 2. The Company operates in one reportable business segment i.e. “Pharmaceuticals”. 3. The figures for the previous year have been regrouped / rearranged wherever considered necessary. 4. The Statutory Auditors have expressed an unqualified opinion on the unaudited Consolidated financials results for the quarter and Nine Month ended 31st December, 2023. Single segment 2023-04-01 2023-12-31 Unaudited Consolidated 834273000.00 11638000.00 845911000.00 235055000.00 102532000.00 -8794000.00 195390000.00 38174000.00 99032000.00 173222000.00 834611000.00 11300000.00 -4348000.00 6952000.00 15257000.00 -2976000.00 12281000.00 0.00 -5329000.00 0.00 0.00 0.00 0.00 -5329000.00 -147000.00 -5476000.00 0.00 193000.00 0.00 0.00 330900000.00 10 -0.19 -0.19 0.00 0.00 -0.19 -0.19 Other Expenses 68532000.00 Other Expenses 173222000.00 110000.00 -147000.00 0.00 0.00 0.00 0.00